Clinical Trial Update: A Study of ABT-263 in Combination With Dose-Intensive Rituximab, or Dose-Intensive Rituximab Alone, in Previously Untreated Patients With B-Cell, Chronic Lymphocytic Leukemia (CLL) [Phase 2]

View source ↗

Summary

This completed Phase 2 study evaluated navitoclax (ABT-263) in combination with dose-intensive rituximab versus rituximab alone in previously untreated B-cell c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Navitoclax (ABT-263) (navitoclax)
• Rituxan (rituximab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: COMPLETED